

# Andreas Thomas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7754981/publications.pdf>

Version: 2024-02-01

163  
papers

5,101  
citations

76326

40  
h-index

133252

59  
g-index

164  
all docs

164  
docs citations

164  
times ranked

2862  
citing authors

#	ARTICLE	IF	CITATIONS
1	First use of the anti- $\alpha$ 2VWF nanobody caplacizumab to treat iTTP in pregnancy. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	17
2	Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 649-659.	3.6	9
3	Urinary phenylethylamine metabolites as potential markers for sports drug testing purposes. <i>Biomedical Chromatography</i> , 2022, 36, e5274.	1.7	4
4	Probing for factors influencing exhaled breath drug testing in sports- Pilot studies focusing on the tested individual's tobacco smoking habit and sex. <i>Rapid Communications in Mass Spectrometry</i> , 2022, 36, e9262.	1.5	4
5	Investigations into the In Vitro Metabolism of hGH and IGF-I Employing Stable-Isotope-Labelled Drugs and Monitoring Diagnostic Immonium Ions by High-Resolution/High-Accuracy Mass Spectrometry. <i>Metabolites</i> , 2022, 12, 146.	2.9	3
6	Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches. <i>Analytica Chimica Acta</i> , 2022, 1202, 339661.	5.4	7
7	Phase I-metabolism studies of the synthetic cannabinoids PX-1 and PX-2 using three different in vitro models. <i>Forensic Toxicology</i> , 2022, 40, 244-262.	2.4	3
8	Probing for the presence of semenogelin in human urine by immunological and chromatographic-mass spectrometric methods in the context of sports drug testing. <i>Analytical Science Advances</i> , 2022, 3, 21-28.	2.8	7
9	Stereoisomers in sports drug testing: Analytical strategies and applications. <i>Journal of Chromatography A</i> , 2022, 1674, 463154.	3.7	4
10	Probing for the presence of doping agents in exhaled breath using chromatographic/mass spectrometric approaches. <i>Rapid Communications in Mass Spectrometry</i> , 2021, 35, e8939.	1.5	9
11	Mass spectrometric identification and characterization of urinary metabolites of isopropylornosynephrine for doping control purposes. <i>Analytical Science Advances</i> , 2021, 2, 334-341.	2.8	4
12	Comprehensive insights into the formation of metabolites of the ghrelin mimetics capmorelin, macimorelin and tabimorelin as potential markers for doping control purposes. <i>Biomedical Chromatography</i> , 2021, 35, e5075.	1.7	5
13	Do dried blood spots have the potential to support result management processes in routine sports drug testing? Part 2: Proactive sampling for follow-up investigations concerning atypical or adverse analytical findings. <i>Drug Testing and Analysis</i> , 2021, 13, 505-509.	2.6	19
14	Facilitated Qualitative Determination of Insulin, Its Synthetic Analogs, and C-Peptide in Human Urine by Means of LC-MS/MS. <i>Metabolites</i> , 2021, 11, 309.	2.9	12
15	Depletion of clomiphene residues in eggs and muscle after oral administration to laying hens. <i>Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment</i> , 2021, 38, 1875-1882.	2.3	6
16	Recent advances in identifying and utilizing metabolites of selected doping agents in human sports drug testing. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 205, 114312.	2.8	15
17	Determination of ghrelin and desacyl ghrelin in human plasma and urine by means of LC-MS/MS for doping controls. <i>Drug Testing and Analysis</i> , 2021, . .	2.6	3
18	Analytical Approaches in Human Sports Drug Testing: Recent Advances, Challenges, and Solutions. <i>Analytical Chemistry</i> , 2020, 92, 506-523.	6.5	39

#	ARTICLE	IF	CITATIONS
19	Simplified quantification of insulin, its synthetic analogs and C-peptide in human plasma by means of LC-HRMS. <i>Drug Testing and Analysis</i> , 2020, 12, 382-390.	2.6	26
20	Identification of metabolites of peptide-derived drugs using an isotope-labeled reporter ion screening strategy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 690-700.	2.3	8
21	Detection of follistatin-based inhibitors of the TGF $\beta$ <sup>2</sup> signaling pathways in serum/plasma by means of LC-HRMS/MS and Western blotting. <i>Drug Testing and Analysis</i> , 2020, 12, 1636-1648.	2.6	8
22	First Steps toward Uncovering Gene Doping with CRISPR/Cas by Identifying SpCas9 in Plasma via HPLC-HRMS/MS. <i>Analytical Chemistry</i> , 2020, 92, 16322-16328.	6.5	13
23	Dietary Supplement and Food Contaminations and Their Implications for Doping Controls. <i>Foods</i> , 2020, 9, 1012.	4.3	74
24	Can dried blood spots (DBS) contribute to conducting comprehensive SARS-CoV-2 antibody tests?. <i>Drug Testing and Analysis</i> , 2020, 12, 994-997.	2.6	37
25	Do dried blood spots (DBS) have the potential to support result management processes in routine sports drug testing?. <i>Drug Testing and Analysis</i> , 2020, 12, 704-710.	2.6	33
26	Dietary $\omega$ -3 and $\omega$ -6 Polyunsaturated fatty acids reconstitute fertility of Juvenile and adult Fads2-Deficient mice. <i>Molecular Metabolism</i> , 2020, 36, 100974.	6.5	31
27	Inter-Laboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured Intact by Mass Spectrometry. <i>Clinical Chemistry</i> , 2020, 66, 579-586.	3.2	17
28	Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 3765-3777.	3.7	40
29	Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). <i>Forensic Science International</i> , 2019, 303, 109925.	2.2	30
30	Development of two complementary LC-HRMS methods for analyzing sotatercept in dried blood spots for doping controls. <i>Bioanalysis</i> , 2019, 11, 923-940.	1.5	16
31	Peptidic drugs and drug candidates in sports drug testing: agents affecting mitochondrial biogenesis or preventing activin receptor II activation. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 9, 22-27.	1.4	5
32	Detection of the myostatin-neutralizing antibody Domagrozumab in serum by means of Western blotting and LC-HRMS. <i>Drug Testing and Analysis</i> , 2019, 11, 1714-1723.	2.6	11
33	Recent advances in the determination of insulins from biological fluids. <i>Advances in Clinical Chemistry</i> , 2019, 93, 115-167.	3.7	22
34	Novel CB1-ligands maintain homeostasis of the endocannabinoid system in $\omega$ -3- and $\omega$ -6-long-chain-PUFA deficiency. <i>Journal of Lipid Research</i> , 2019, 60, 1396-1409.	4.2	5
35	In vitro metabolic profiling of synthetic cannabinoids by pooled human liver microsomes, cytochrome P450 isoenzymes, and <i>Cunninghamella elegans</i> and their detection in urine samples. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 3561-3579.	3.7	15
36	Phase I metabolic profiling of the synthetic cannabinoids THJ-018 and THJ-2201 in human urine in comparison to human liver microsome and cytochrome P450 isoenzyme incubation. <i>International Journal of Legal Medicine</i> , 2019, 133, 1049-1064.	2.2	8

#	ARTICLE	IF	CITATIONS
37	Development of a mass spectrometry based detection method for the mitochondrionâ€derived peptide MOTSA€ in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry, 2019, 33, 371-380.	1.5	16
38	Organ distribution of 4-MEC, MDPV, methoxetamine and Î±-PVP: comparison of QuEChERS and SPE. Forensic Toxicology, 2018, 36, 320-333.	2.4	17
39	Analytical challenges in sports drug testing. Analytical and Bioanalytical Chemistry, 2018, 410, 2275-2281.	3.7	12
40	Detection of the Human Antiâ€ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LCâ€HRMS. Proteomics - Clinical Applications, 2018, 12, e1700120.	1.6	12
41	Effects of different exercise intensities in the morning on football performance components in the afternoon. German Journal of Exercise and Sport Research, 2018, 48, 235-244.	1.2	4
42	Combined detection of the ActRIIâ€Fc fusion proteins Sotatercept (ActRIIAâ€Fc) and Luspatercept (modified) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Testing and Analysis, 2018, 10, 1714-1721.	2.6	14
43	Analysis of insulin and insulin analogs from dried blood spots by means of liquid chromatographyâ€high resolution mass spectrometry. Drug Testing and Analysis, 2018, 10, 1761-1768.	2.6	31
44	Recent improvements in sports drug testing concerning the initial testing for peptidic drugs (&t;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2018, 10, 1755-1760.	2.6	22
45	Post-mortem distribution of the synthetic cannabinoid MDMB-CHMICA and its metabolites in a case of combined drug intoxication. International Journal of Legal Medicine, 2018, 132, 1645-1657.	2.2	10
46	Analysis of new growth promoting black market products. Growth Hormone and IGF Research, 2018, 41, 1-6.	1.1	11
47	Simultaneous determination of insulin, DesB30 insulin, proinsulin, and C-peptide in human plasma samples by liquid chromatography coupled to high resolution mass spectrometry. Forensic Toxicology, 2017, 35, 106-113.	2.4	20
48	Characterization of <i>in vitro</i> generated metabolites of selected peptides &t;2ÂkDa prohibited in sports. Drug Testing and Analysis, 2017, 9, 1799-1803.	2.6	15
49	Immunoaffinity techniques coupled to mass spectrometry for the analysis of human peptide hormones: advances and applications. Expert Review of Proteomics, 2017, 14, 799-807.	3.0	20
50	Determination of LongR 3 -IGF-I, R 3 -IGF-I, Des1-3 IGF-I and their metabolites in human plasma samples by means of LC-MS. Growth Hormone and IGF Research, 2017, 35, 33-39.	1.1	12
51	Simplifying and expanding the screening for peptides &t;2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. Journal of Separation Science, 2016, 39, 333-341.	2.5	40
52	Identification of Selected <i>in vitro</i>-Generated Phase-I Metabolites of the Steroidal Selective Androgen Receptor Modulator MK-0773 for Doping Control Purposes. European Journal of Mass Spectrometry, 2016, 22, 49-59.	1.0	12
53	Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 131, 482-496.	2.8	48
54	Testing for the erythropoiesisâ€stimulating agent Sotatercept/ACEâ€011 (ActRIIAâ€Fc) in serum by means of Western blotting and LCâ€HRMS. Drug Testing and Analysis, 2016, 8, 1152-1161.	2.6	24

#	ARTICLE	IF	CITATIONS
55	Analytics of nonpeptidic erythropoietin mimetic agents in sports drug testing employing high-resolution/high-accuracy liquid chromatography-mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 6431-6442.	3.7	2
56	In vitro elucidation of the metabolic profile of the synthetic cannabinoid receptor agonists JWH-175 and JWH-176. <i>Forensic Toxicology</i> , 2016, 34, 353-362.	2.4	6
57	Myostatin inhibitors in sports drug testing: Detection of myostatin-neutralizing antibodies in plasma/serum by affinity purification and Western blotting. <i>Proteomics - Clinical Applications</i> , 2016, 10, 195-205.	1.6	10
58	Identification and characterization of in vitro and in vivo generated metabolites of the adiponectin receptor agonists AdipoRon and 112254. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 125, 68-76.	2.8	13
59	Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 123, 132-140.	2.8	39
60	Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 3145-3153.	3.7	30
61	Factitious administration of analogue insulin to a 2-year-old child. <i>British Journal of Diabetes</i> , 2016, 16, 82.	0.2	6
62	Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. <i>Drug Testing and Analysis</i> , 2015, 7, 919-925.	2.6	35
63	Complementing the characterization of in vivo generated N-glycuronic acid conjugates of stanozolol by collision cross section computation and analysis. <i>Drug Testing and Analysis</i> , 2015, 7, 1050-1056.	2.6	17
64	Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 991-999.	1.5	33
65	Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS. <i>Drug Testing and Analysis</i> , 2015, 7, 990-998.	2.6	33
66	Formation of the diuretic chlorazasil from the antimalarial drug proguanil—Implications for sports drug testing. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 208-213.	2.8	10
67	EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS. <i>Journal of the American Society for Mass Spectrometry</i> , 2015, 26, 1617-1625.	2.8	6
68	Determination of Synacthen® in dried blood spots for doping control analysis using liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 4709-4720.	3.7	24
69	“Dilute-and-inject” multi-target screening assay for highly polar doping agents using hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry for sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 5365-5379.	3.7	48
70	Metabolism of human insulin after subcutaneous administration: A possible means to uncover insulin misuse. <i>Analytica Chimica Acta</i> , 2015, 897, 53-61.	5.4	23
71	Dried blood spots (DBS) in doping controls: a complementary matrix for improved in- and out-of-competition sports drug testing strategies. <i>Analytical Methods</i> , 2015, 7, 7596-7605.	2.7	23
72	Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. <i>Expert Review of Proteomics</i> , 2014, 11, 663-673.	3.0	26

#	ARTICLE	IF	CITATIONS
73	Determination of human insulin and its analogues in human blood using liquid chromatography coupled to ion mobility mass spectrometry (LC-IM-MS). <i>Drug Testing and Analysis</i> , 2014, 6, 1125-1132.	2.6	62
74	Isolation, Enrichment, and Analysis of Erythropoietins in Anti-Doping Analysis by Receptor-Coated Magnetic Beads and Liquid Chromatography-Mass Spectrometry. <i>Analytical Chemistry</i> , 2014, 86, 12014-12021.	6.5	17
75	Detection of an unknown fusion protein in confiscated black market products. <i>Drug Testing and Analysis</i> , 2014, 6, 1117-1124.	2.6	13
76	Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls. <i>Growth Hormone and IGF Research</i> , 2014, 24, 276-280.	1.1	15
77	Determination of <sup>13</sup> C/ <sup>12</sup> C ratios of endogenous urinary 5-aminimidazole-4-carboxamide 1 $\beta$ -ribofuranoside (AICAR). <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1194-1202.		22
78	Use of dried blood spots in doping control analysis of anabolic steroid esters. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 96, 21-30.	2.8	51
79	Measuring xenon in human plasma and blood by gas chromatography/mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1501-1506.	1.5	25
80	Isotope dilution mass spectrometric quantification of the prodrug lisdexamfetamine in human urine in doping control analysis. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 781-786.	1.5	6
81	Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches. <i>Drug Testing and Analysis</i> , 2014, 6, 1197-1205.	2.6	16
82	Interlaboratory Agreement of Insulin-like Growth Factor 1 Concentrations Measured by Mass Spectrometry. <i>Clinical Chemistry</i> , 2014, 60, 541-548.	3.2	96
83	Identification of black market products and potential doping agents in Germany 2010-2013. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1303-1311.	1.9	84
84	Quantification of intact human insulin-like growth factor-1 in serum by nano-ultrahigh-performance liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2014, 28, 1426-1432.	1.5	30
85	Liquid Chromatography-High Resolution/High Accuracy (Tandem) Mass Spectrometry-Based Identification of <i>in vivo</i> Generated Metabolites of the Selective Androgen Receptor Modulator ACP-105 for Doping Control Purposes. <i>European Journal of Mass Spectrometry</i> , 2014, 20, 73-83.	1.0	16
86	Traditional Chinese medicine and sports drug testing: identification of natural steroid administration in doping control urine samples resulting from musk (pod) extracts. <i>British Journal of Sports Medicine</i> , 2013, 47, 109-114.	6.7	37
87	Quantification of AICAR-ribotide concentrations in red blood cells by means of LC-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9703-9709.	3.7	19
88	Expanding analytical possibilities concerning the detection of stanozolol misuse by means of high resolution/high accuracy mass spectrometric detection of stanozolol glucuronides in human sports drug testing. <i>Drug Testing and Analysis</i> , 2013, 5, 810-818.	2.6	62
89	Targeting prohibited substances in doping control blood samples by means of chromatographic-mass spectrometric methods. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9655-9667.	3.7	20
90	Detection of small interfering RNA (siRNA) by mass spectrometry procedures in doping controls. <i>Drug Testing and Analysis</i> , 2013, 5, 853-860.	2.6	17

#	ARTICLE	IF	CITATIONS
91	Combination of carbon isotope ratio with hydrogen isotope ratio determinations in sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 5455-5466.	3.7	36
92	Does the analysis of the enantiomeric composition of clenbuterol in human urine enable the differentiation of illicit clenbuterol administration from food contamination in sports drug testing?. <i>Rapid Communications in Mass Spectrometry</i> , 2013, 27, 507-512.	1.5	46
93	Effect of changes in the deuterium content of drinking water on the hydrogen isotope ratio of urinary steroids in the context of sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 2911-2921.	3.7	2
94	Post-mortem vitreous humour as potential specimen for detection of insulin analogues by LC-MS/MS. <i>Forensic Science International</i> , 2013, 233, 328-332.	2.2	26
95	Gender differences in the bronchoalveolar lavage cell proteome of patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 743-751.e9.	2.9	58
96	Ultrahigh pressure liquid chromatography-(tandem) mass spectrometry in human sports drug testing: Possibilities and limitations. <i>Journal of Chromatography A</i> , 2013, 1292, 38-50.	3.7	41
97	Effects of gamma irradiation and 15 days of subsequent ex vivo storage on the cytosolic red blood cell proteome analyzed by 2D-DIGE and Orbitrap MS. <i>Proteomics - Clinical Applications</i> , 2013, 7, 561-570.	1.6	5
98	Detection of Peginesatide in Equine Serum Using Liquid Chromatography-Tandem Mass Spectrometry for Doping Control Purposes. <i>European Journal of Mass Spectrometry</i> , 2012, 18, 407-412.	1.0	6
99	Mass spectrometric detection of peginesatide in human urine in doping control analysis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 70, 512-517.	2.8	14
100	Investigations on hydrogen isotope ratios of endogenous urinary steroids: reference-population-based thresholds and proof-of-concept. <i>Drug Testing and Analysis</i> , 2012, 4, 717-727.	2.6	32
101	Influence of repeated subcutaneous G-CSF injections on selected blood parameters relevant for monitoring programmes in sports drug testing. <i>Drug Testing and Analysis</i> , 2012, 4, 798-802.	2.6	3
102	Storage-induced changes of the cytosolic red blood cell proteome analyzed by 2D DIGE and high-resolution/high-accuracy MS. <i>Proteomics</i> , 2012, 12, 3263-3272.	2.2	17
103	Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls. <i>Methods</i> , 2012, 56, 230-235.	3.8	85
104	Metabolism of Growth Hormone Releasing Peptides. <i>Analytical Chemistry</i> , 2012, 84, 10252-10259.	6.5	47
105	Validated hemoglobin-depletion approach for red blood cell lysate proteome analysis by means of 2D PAGE and Orbitrap MS. <i>Electrophoresis</i> , 2012, 33, 2537-2545.	2.4	19
106	Characterization of In Vitro Synthesized Equine Metabolites of the Selective Androgen Receptor Modulators S24 and S4. <i>Journal of Equine Veterinary Science</i> , 2012, 32, 562-568.	0.9	13
107	Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry. <i>Journal of Chromatography A</i> , 2012, 1259, 251-257.	3.7	54
108	Simultaneous determination and validated quantification of human insulin and its synthetic analogues in human blood serum by immunoaffinity purification and liquid chromatography-mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 404, 1813-1822.	3.7	65

#	ARTICLE	IF	CITATIONS
109	Analysis of octopamine in human doping control samples. <i>Biomedical Chromatography</i> , 2012, 26, 610-615.	1.7	11
110	Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 2715-2724.	3.7	58
111	Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 1279-1289.	3.7	136
112	Measuring insulin in human vitreous humour using LC-MS/MS. <i>Drug Testing and Analysis</i> , 2012, 4, 53-56.	2.6	42
113	Structure Elucidation of the Diagnostic Product Ion at m/z 97 Derived from Androst-4-en-3-One-Based Steroids by ESI-CID and IRMPD Spectroscopy. <i>Journal of the American Society for Mass Spectrometry</i> , 2012, 23, 537-546.	2.8	23
114	Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. <i>Analyst</i> , The, 2011, 136, 1003-1012.	3.5	57
115	Determination of Vasopressin and Desmopressin in urine by means of liquid chromatography coupled to quadrupole time-of-flight mass spectrometry for doping control purposes. <i>Analytica Chimica Acta</i> , 2011, 707, 107-113.	5.4	47
116	Doping control analysis of selected peptide hormones using LC-MS(/MS). <i>Forensic Science International</i> , 2011, 213, 35-41.	2.2	39
117	Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. <i>Drug Testing and Analysis</i> , 2011, 3, 609-620.	2.6	113
118	Trafficking of drug candidates relevant for sports drug testing: Detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. <i>Drug Testing and Analysis</i> , 2011, 3, 331-336.	2.6	45
119	Dried blood spots (DBS) for doping control analysis. <i>Drug Testing and Analysis</i> , 2011, 3, 806-813.	2.6	42
120	Identification of fibroblast growth factor 1 (FGF-1) in a black market product. <i>Drug Testing and Analysis</i> , 2011, 3, 791-797.	2.6	16
121	Screening for benfluorex and its major urinary metabolites in routine doping controls. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 543-551.	3.7	11
122	Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 507-516.	3.7	83
123	Current role of LC-MS(/MS) in doping control. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 405-420.	3.7	86
124	Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 493-505.	3.7	66
125	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator SARM-1 to identify potential targets for routine doping controls. <i>Rapid Communications in Mass Spectrometry</i> , 2011, 25, 2187-2195.	1.5	38
126	Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes. <i>Rapid Communications in Mass Spectrometry</i> , 2011, 25, 2115-2123.	1.5	33



#	ARTICLE	IF	CITATIONS
127	Mass Spectrometry-Based Characterization of New Drugs and Methods of Performance Manipulation in Doping Control Analysis. <i>European Journal of Mass Spectrometry</i> , 2010, 16, 301-312.	1.0	12
128	Identification of the growth hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement. <i>Drug Testing and Analysis</i> , 2010, 2, 144-148.	2.6	52
129	Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the cologne doping control laboratory 2009. <i>Drug Testing and Analysis</i> , 2010, 2, 533-537.	2.6	92
130	Characterization of <i>in vitro</i> generated metabolites of the selective androgen receptor modulators Sâ€22 and Sâ€23 and <i>in vivo</i> comparison to post-administration canine urine specimens. <i>Drug Testing and Analysis</i> , 2010, 2, 589-598.	2.6	41
131	Characterization of two major urinary metabolites of the PPAR $\gamma$ -agonist GW1516 and implementation of the drug in routine doping controls. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2479-2491.	3.7	43
132	Quantification of urinary AICAR concentrations as a matter of doping controls. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2899-2908.	3.7	34
133	Mass spectrometric detection of siRNA in plasma samples for doping control purposes. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 398, 1305-1312.	3.7	22
134	Effects of endurance exercise on the urinary proteome analyzed by 2D PAGE and Orbitrap MS. <i>Proteomics - Clinical Applications</i> , 2010, 4, 568-576.	1.6	24
135	Comprehensive plasma screening for known and unknown substances in doping controls. <i>Rapid Communications in Mass Spectrometry</i> , 2010, 24, 1124-1132.	1.5	60
136	Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (Sâ€4) for routine doping control purposes. <i>Rapid Communications in Mass Spectrometry</i> , 2010, 24, 2245-2254.	1.5	48
137	Detection of Surreptitious Administration of Analog Insulin to an 8-Week-Old Infant. <i>Pediatrics</i> , 2010, 125, e1236-e1240.	2.1	39
138	Detection of His-tagged Long-R3-IGF-I in a black market product. <i>Growth Hormone and IGF Research</i> , 2010, 20, 386-390.	1.1	33
139	Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. <i>Journal of Mass Spectrometry</i> , 2009, 44, 442-460.	1.6	56
140	Doping control analysis of emerging drugs in human plasma – identification of GW501516, Sâ€107, JTVâ€519, and Sâ€40503. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 1139-1146.	1.5	34
141	Electron ionization mass spectrometry of the ryanodine receptor-based Ca <sup>2+</sup> -channel stabilizer S-107 and its implementation into routine doping control. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 2363-2370.	1.5	10
142	Determination of Synacthen in urine for sports drug testing by means of nano-ultra-performance liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 2669-2674.	1.5	38
143	Insulin. <i>Handbook of Experimental Pharmacology</i> , 2009, , 209-226.	1.8	45
144	Screening for the calstabin $\gamma$ -ryanodine receptor complex stabilizers JTVâ€519 and Sâ€107 in doping control analysis. <i>Drug Testing and Analysis</i> , 2009, 1, 32-42.	2.6	15

#	ARTICLE	IF	CITATIONS
145	Proteolysis and autolysis of proteases and the detection of degradation products in doping control. <i>Drug Testing and Analysis</i> , 2009, 1, 81-86.	2.6	24
146	Detection of the protease Bacillolysin in doping control urine samples. <i>Drug Testing and Analysis</i> , 2009, 1, 143-145.	2.6	12
147	Sensitive and fast identification of urinary human, synthetic and animal insulin by means of nano-UPLC coupled with high-resolution/high-accuracy mass spectrometry. <i>Drug Testing and Analysis</i> , 2009, 1, 219-227.	2.6	72
148	Application of FAIMS to anabolic androgenic steroids in sport drug testing. <i>Drug Testing and Analysis</i> , 2009, 1, 545-553.	2.6	44
149	Comparison of the urinary protein patterns of athletes by 2D-gel electrophoresis and mass spectrometry—a pilot study. <i>Drug Testing and Analysis</i> , 2009, 1, 382-386.	2.6	21
150	Identification of Human Pituitary Growth Hormone Variants by Mass Spectrometry. <i>Journal of Proteome Research</i> , 2009, 8, 1071-1076.	3.7	40
151	Doping Control Analysis of Metamfepramone and Two Major Metabolites Using Liquid Chromatography-Tandem Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2009, 15, 507-515.	1.0	8
152	Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 391, 251-261.	3.7	40
153	Insulins in equine urine: qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horse racing. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 355-362.	1.5	36
154	Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 2471-2478.	1.5	36
155	Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS. <i>Journal of Mass Spectrometry</i> , 2008, 43, 908-915.	1.6	62
156	Mass spectrometric determination of insulins and their degradation products in sports drug testing. <i>Mass Spectrometry Reviews</i> , 2008, 27, 35-50.	5.4	98
157	Rapid screening of polysaccharide-based plasma volume expanders dextran and hydroxyethyl starch in human urine by liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2008, 22, 695-701.	1.7	25
158	Analysis of Confiscated Black Market Drugs Using Chromatographic and Mass Spectrometric Approaches. <i>Journal of Analytical Toxicology</i> , 2008, 32, 232-240.	2.8	62
159	Determination of Selected Stimulants in Urine for Sports Drug Analysis by Solid Phase Extraction via Cation Exchange and Means of Liquid Chromatography-Tandem Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 135-143.	1.0	21
160	Mass Spectrometric Identification of Degradation Products of Insulin and Its Long-Acting Analogues in Human Urine for Doping Control Purposes. <i>Analytical Chemistry</i> , 2007, 79, 2518-2524.	6.5	75
161	Doping Control Analysis of Intact Rapid-Acting Insulin Analogues in Human Urine by Liquid Chromatography-Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2006, 78, 1897-1903.	6.5	91
162	Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 2252-2258.	1.5	114

#	ARTICLE	IF	CITATIONS
163	Qualitative Determination of Synthetic Analogues of Insulin in Human Plasma by Immunoaffinity Purification and Liquid Chromatography-Tandem Mass Spectrometry for Doping Control Purposes. Analytical Chemistry, 2005, 77, 3579-3585.	6.5	105